Navigation Links
New Hope For Patients With Relapsing Multiple Sclerosis

Over two million people worldwide are estimated to suffer from multiple sclerosis (MS), which is the leading cause of neurological disability in young adults, and has a significant impact on the overall quality of life. // Currently marketed therapies afford an average reduction in relapse rates of 30% in two-year studies and require frequent injections ranging from daily to weekly.

Data from the extension of a Phase II study to 12 months conducted by Novartis Pharma confirm the significant effects of FTY720, a novel oral medication, for the treatment of patients with relapsing MS. The data, presented at the ECTRIMS/ACTRIMS meeting in Thessalonica, Greece, showed that patient groups taking FTY720 who had experienced a reduction in their annualized relapse rate of more than 50% during the first 6 months of the study compared to placebo maintained this low relapse rate during the subsequent 6-month extension. More than 80% patients who received FTY720 for up to 12 months were free from lesions showing active inflammation on magnetic resonance imaging (MRI) at month twelve irrespective of their FTY720 treatment dose.

In a press release, chief investigator Professor Ludwig Kappos, MD, Department of Neurology at the University Hospital in Basel, Switzerland said "We are excited by these full-year study results confirming the significant effect of oral FTY720 on reducing both clinical relapses and inflammatory disease activity that we first saw during the 6-month placebo-controlled phase of the study. FTY720 appeared to be well tolerated; there were no complications during the extension as compared to the 6-month placebo-controlled phase.

According to the press release, oral FTY720 has a novel mode of action different from all available therapies. It reversibly sequesters lymphocytes away from blood and susceptible target organs such as the central nervous system (CNS), thereby reducing neuroinflammation in MS. FTY720 has been developed b y Novartis Pharma and licensed from Mitsubishi Pharma Corporation.

Based on the positive results of the Phase II study conducted at 32 centers in 11 countries (Europe and Canada), Novartis is in discussions with regulatory authorities about the FTY720 Phase III program, which is expected to be launched by the end of 2005.
'"/>




Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patients often assume wrongly that they are allergic to penicillin
7. New FDA Approved Drug NATRECOR For Heart Failure Patients
8. Hemochromatosis Patients Blood is Safe
9. Patients Pressure Would Result In Overprescription
10. Risk Of Decongestants In Hypertensive Patients
11. Interference helps Heart Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/16/2017)... ... August 16, 2017 , ... ... through affiliations and de novo development, today announced Cumberland Skin Surgery and ... Skin Surgery and Dermatology, with offices in both Hermitage and Lebanon, Tennessee, provides ...
(Date:8/16/2017)... Kansas City, KS (PRWEB) , ... August 16, ... ... announced the latest beneficiary of their recently launched community enrichment program. Partnering once ... fundraising for the KC Superstar competition to help find the area’s very own ...
(Date:8/16/2017)... ... 16, 2017 , ... Maury Regional Health has announced a large-scale adoption of ... AccuVein devices, Maury Regional Medical Center is making vein visualization part of their standard ... stick and more importantly, helps our staff members locate a vein that will provide ...
(Date:8/16/2017)... ... 16, 2017 , ... The Southeastern Telehealth Resource Center at ... renewing its funding from the Health Resources and Services Administration (HRSA), part of ... fourth time the HRSA administration has renewed its financial support to GPT since ...
(Date:8/16/2017)... ... ... Paul Vitenas, MD, FACS , is honored to announce that he has ... nation’s top physicians, in a variety of specialties. This marks the fourth year in ... coveted ranking. , Castle Connolly is the nation’s trusted provider of information on the ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... HOUSTON , Aug. 15, 2017   Mostyn Law ... in Houston, Texas . The Mostyn Law ... the past 2 years. That is why Mostyn Law ... Texas to show its appreciation. Blood supplies ... to fall 5% short of hospital needs in August. That is ...
(Date:8/15/2017)... Aug. 15, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Michigan residents. Naloxone is ... retail pharmacy, G-3320 Beecher Road. ... Food and Drug Administration, is intended to block or ... breathing, and loss of consciousness. The medication is often ...
(Date:8/15/2017)... , Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of ... to be in the beginning stages of an IPO. ... epilepsy medications with the average cost of a prescription epilepsy drug being ... AXIUM ... Another staggering figure is the fact that ...
Breaking Medicine Technology: